c o r e t v a s a 5 6 ( 2 0 1 4 ) e 3 2 0 -e 3 2 4 Acute coronary syndrome Myocardial infarction Ticagrelor Prasugrel Clopidogrel Antiplatelet therapy a b s t r a c t Background: The modern treatment of acute coronary syndromes includes early initiation of dual antiplatelet therapy (DAPT) and coronary angiography (CAG) followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Recently two new potent antiplatelet agents (ticagrelor and prasugrel) were introduced in clinical practice. The aim of this registry was to analyze the treatment strategies in two neighboring countries: Czech (CZ) and Slovak (SK) Republics.
Introduction
The European Society of Cardiology (ESC) and the Czech/ Slovak Society of Cardiology guidelines [1-5] for treatment of acute coronary syndromes (ACS) recommend the initiation of dual antiplatelet therapy (DAPT) early after the diagnosis of an acute coronary syndrome was established. Coronary angiography (CAG) followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) should be performed early, especially in the high risk patients.
The introduction of the high-sensitivity cardiac troponin assays modified the spectrum of ACS in such ways, that unstable angina is decreasing and non-STEMI rates are increasing [6] . The widespread use of emergent CAG AE PCI in STEMI and in high risk non-STEMI led to a proposal to change the classification of acute coronary syndromes and to replace the ECG-based classification by an ongoing ischemiabase classification [7] .
Recently two new potent antiplatelet agents (ticagrelor and prasugrel) were introduced in clinical practice after two major randomized trials proved their superiority over clopidogrel [8, 9] . The aim of this registry was to analyze the treatment strategies in two neighbor countries: Czech and Slovak republics.
Patients and methods
All consecutive patients, who were discharged home or transferred to other hospital from PCI centers in the Czech and Slovak republics during one month (in 2013), were the subjects of the observation. Dataset was collected in electronic clinical data management system, which is originally based on a modified version of TrialDB system [10] . This on-line system, widely accessible via a standard Internet browser, was customized for the collection of specific clinical data of the current study. Control mechanisms were added to improve quality of data.
Standard descriptive statistics were applied in the analysis; absolute and relative frequencies for categorical variables and mean supplemented by standard deviation for continuous variables. Statistical significance of differences between groups of patients was tested using maximum likelihood chi-square test and independent t-test for continuous variables. Analysis was computed using SPSS 22 (IBM Corporation, 2013).
A total of 1541 patients were enrolled during one month period in 18 tertiary cardiac centers in the Czech Republic (n = 1026) and 6 centers in the Slovak Republic (n = 515). The comparison of baseline characteristics is given in Table 1 .
Results
The main results of the registry are given in Table 2 . STsegment elevation myocardial infarction (STEMI) was the final diagnosis in 51.9% (CZ) vs. 44.9% (SK), non-STEMI in 34.1% vs. 31.3% and unstable angina pectoris (UAP) in 14.0% vs. 23.9%. PCI during the initial hospital stay was performed in 83.4% (CZ) vs. 78.8% (SK). The discharge medication included aspirin in 95.3% (both countries), clopidogrel in 75.3% (CZ) vs. 53.6% (SK), ticagrelor in 13.1% (CZ) vs. 17.3% (SK) and prasugrel in 2.6% (CZ) vs. 23.1% (SK). Economic limits were reported to influence the choice of P2Y12 inhibitor in 36.9% (CZ) vs. 23.9% (SK).
The indication for ticagrelor was in STEMI 73.9% (CZ) vs. 36.0% (SK), non-STEMI in 20.9% (CZ) vs. 40.4% (SK) and UAP in 5.2% (CZ) vs. 23.6% (SK). The indication for prasugrel was STEMI in 81.5% (CZ) vs. 73.9% (SK), non-STEMI in 18.5% (CZ) vs. 11.8% (SK) and UAP in 0.0% (CZ) vs. 14.3% (SK).
Conclusions:
The baseline characteristics of ACS patients are similar in both countries, and the Czech patients tend to be older and have more prior revascularizations. Slovak patients receive more often modern potent P2Y12 inhibitors. The results confirm existing economic barriers preventing full implementation of the antiplatelet recommendations from the current ESC guidelines, but also lack of guidelines knowledge (or implementation) among some physicians.
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Discussion
Published registries on acute coronary syndromes are usually focused on patients' outcomes and general information about treatment strategies, but only limited information about the details of antiplatelet therapy is provided. No such information was available from the Czech and Slovak republics. ATHRO is the first systematic evaluation of antiplatelet therapy in acute coronary syndromes in both participating countries. The ATHRO registry in comparison with SLOVAKS-2 registry [11] and the Slovak Society of Cardiology guidelines showed increased use of the novel antiplatelets agents ticagrelor and prasugrel in patients with ACS in the Slovak Republic. Ticagrelor was not used in patients enrolled to the SLOVAKS-2 registry, but was used in 17.3% of ACS patients in ATHRO. Similarly, the use of prasugrel in STEMI increased from 6.6% (SLOVAKS-2) to 23.1% (ATHRO). These trends are reflecting the improved implementation of the latest guidelines [1] [2] [3] [4] [5] .
Despite the economic barriers, the use of the novel antiplatelet agents significantly increased (40.4% at discharge) in Slovakia during 2013, but the existing prescription limitations and suboptimal guidelines implementation remain to cause less than ideal use of these agents in everyday practice. The advantages of ticagrelor include its proven efficacy in patients pretreated with clopidogrel and in patients treated without PCI (i.e. medically or surgically). Prasugrel main advantage is its proven efficacy in patients receiving stents, especially for acute STEMI.
The CZECH-2 registry [12] demonstrated that on admission the following medications are used by the patients: 39.8% aspirin; 7.6% clopidogrel and 8.7% oral anticoagulants. At discharge, the following medications were administered: aspirin 93.5%; clopidogrel 76.4%; prasugrel 0.6%; ticagrelor 0.8%; oral anticoagulation 9.5%. ATHRO showed also positive trends in the Czech Republic, but to a lesser degree than in Slovakia.
As the economic and/or prescribing (indication) limits play a major role in the selection of P2Y12 inhibitor by a physician for a given patient, we provide detailed information on this topic in Table 3 . This table clearly explains the differences in novel antiplatelet drug use: prasugrel is three times more expensive for the Czech patients than for their Slovak counterparts and ticagrelor is twice more expensive for the Czech patients. This is an indirect confirmation of the well known fact, that the drug price for the patient (how much he/she has to pay in the pharmacy) is the most important driver of treatment selection.
Generally in Czech and Slovak republics the indication for prasugrel in non-STE ACS was not yet influenced by publications of the TRILOGY ACS trial results [13] .
Conclusions
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